Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers.

Hida,Y; Morita,T; Fujita,M; Miyasaka,Y; Horita,S; Fujioka,Y; Nagashima,K; Katoh,H

doi:10.3892/or.6.5.1051

Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers.

Authors:
- Y Hida
- T Morita
- M Fujita
- Y Miyasaka
- S Horita
- Y Fujioka
- K Nagashima
- H Katoh
View Affiliations

Affiliations: Second Department of Surgery, School of Medicine, Hokkaido University, Kita-Ku, Sapporo 060-8638, Japan.
Published online on: September 1, 1999 https://doi.org/10.3892/or.6.5.1051
Pages: 1051-1057

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocyte growth factor (HGF)/c-Met expression is known to be correlated with poor prognosis in several cancers. We investigated HGF/c-Met immunoreactivity and its correlation with clinical features in 51 patients with curatively resected extrahepatic biliary tract carcinoma. c-Met showed significant correlations with tumor location, T category, stage, perineural invasion and local recurrence. Overall survival in patients with HGF and c-Met immunopositivity was significantly worse than in those who were negative. Our findings suggest that HGF/c-Met play some roles in tumor development and that HGF/c-Met immunoreactivity could be a predictor of the mode of recurrence and poor prognosis.